KR100971616B1 - 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 - Google Patents
결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR100971616B1 KR100971616B1 KR1020037016769A KR20037016769A KR100971616B1 KR 100971616 B1 KR100971616 B1 KR 100971616B1 KR 1020037016769 A KR1020037016769 A KR 1020037016769A KR 20037016769 A KR20037016769 A KR 20037016769A KR 100971616 B1 KR100971616 B1 KR 100971616B1
- Authority
- KR
- South Korea
- Prior art keywords
- crystalline
- tiotropium
- anhydrous
- brominated
- brominated tiotropium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 230000001078 anti-cholinergic effect Effects 0.000 title abstract description 5
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title description 8
- -1 hydroxydi-2-thienylacetyl Chemical group 0.000 claims abstract description 30
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 63
- 238000001035 drying Methods 0.000 claims description 7
- 238000012916 structural analysis Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 abstract description 15
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 208000006673 asthma Diseases 0.000 abstract description 3
- VTTKBFMNVGIDQJ-UHFFFAOYSA-N nonane;hydrobromide Chemical compound Br.CCCCCCCCC VTTKBFMNVGIDQJ-UHFFFAOYSA-N 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 42
- 239000000843 powder Substances 0.000 description 31
- 239000000203 mixture Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 239000013543 active substance Substances 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- 229940110309 tiotropium Drugs 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960000257 tiotropium bromide Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012982 x-ray structure analysis Methods 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 238000003991 Rietveld refinement Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129710.6 | 2001-06-22 | ||
| DE10129710 | 2001-06-22 | ||
| DE10215436.8 | 2002-04-08 | ||
| DE10215436 | 2002-04-08 | ||
| PCT/EP2002/006291 WO2003000265A1 (de) | 2001-06-22 | 2002-06-08 | Kristallines anticholinergikum, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097004823A Division KR101011353B1 (ko) | 2001-06-22 | 2002-06-08 | 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040018285A KR20040018285A (ko) | 2004-03-02 |
| KR100971616B1 true KR100971616B1 (ko) | 2010-07-22 |
Family
ID=26009556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020037016769A Expired - Lifetime KR100971616B1 (ko) | 2001-06-22 | 2002-06-08 | 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| KR1020097004823A Expired - Lifetime KR101011353B1 (ko) | 2001-06-22 | 2002-06-08 | 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097004823A Expired - Lifetime KR101011353B1 (ko) | 2001-06-22 | 2002-06-08 | 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
Country Status (37)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10212264A1 (de) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US20050038004A1 (en) * | 2003-07-31 | 2005-02-17 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| WO2005042527A1 (de) * | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Neues kristallines anhydrat mit anticholinerger wirksamkeit |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| EP1781298B1 (de) | 2004-04-22 | 2012-01-04 | Boehringer Ingelheim International GmbH | Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen |
| DE102004024454A1 (de) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| ES2322148T3 (es) | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias. |
| US20060079544A1 (en) * | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| DE102004048389A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa |
| KR20080007645A (ko) | 2005-04-28 | 2008-01-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환 치료용 신규 화합물 |
| EP1879888A2 (en) * | 2005-05-02 | 2008-01-23 | Boehringer Ingelheim International GmbH | Crystalline forms of tiotropium bromide |
| KR20080012932A (ko) * | 2005-05-02 | 2008-02-12 | 베링거 인겔하임 인터내셔날 게엠베하 | 티오트로퓸 브로마이드의 신규한 결정형 |
| DE102005030733A1 (de) | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
| EP1917253B1 (de) | 2005-08-15 | 2015-01-07 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von betamimetika |
| US20070086957A1 (en) * | 2005-10-10 | 2007-04-19 | Thierry Bouyssou | Combination of medicaments for the treatment of respiratory diseases |
| US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
| US9108962B2 (en) | 2005-12-19 | 2015-08-18 | Sicor, Inc. | Forms of tiotropium bromide and processes for preparation thereof |
| PT1869035E (pt) | 2005-12-19 | 2013-01-10 | Sicor Inc | Novas formas de brometo de tiotrópio e processos para sua preparação |
| CN100999521B (zh) * | 2006-01-13 | 2010-12-08 | 江苏正大天晴药业股份有限公司 | 结晶性抗胆碱药噻托溴铵 |
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| HRP20090395T1 (hr) | 2006-04-19 | 2009-08-31 | Boehringer Ingelheim International Gmbh | Dihidrotienpirimidini za liječenje upalnih bolesti |
| JP2010500318A (ja) | 2006-08-07 | 2010-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療用医薬組成物 |
| PE20080610A1 (es) | 2006-08-22 | 2008-07-15 | Boehringer Ingelheim Int | Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos |
| GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| SI2610258T1 (sl) | 2007-10-19 | 2014-12-31 | Boehringer Ingelheim International Gmbh | Substituirani piperidino-dihidrotienopirimidini |
| EP2093219A1 (de) | 2008-02-22 | 2009-08-26 | Boehringer Ingelheim International Gmbh | Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel |
| ES2551557T3 (es) | 2008-12-19 | 2015-11-19 | Boehringer Ingelheim International Gmbh | Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC |
| EP2403851B1 (en) | 2009-03-06 | 2015-06-17 | Mahmut Bilgic | New crystalline forms of tiotropium bromide |
| PL2513093T3 (pl) | 2009-12-17 | 2015-03-31 | Centrexion Therapeutics Corp | Nowi antagoniści receptora CCR2 i ich zastosowanie |
| WO2011073155A1 (en) | 2009-12-17 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Novel antagonists for ccr2 and uses thereof |
| CA2786245A1 (en) | 2010-01-29 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and their use as syk kinase inhibitors |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2569295B1 (en) | 2010-05-12 | 2014-11-19 | Boehringer Ingelheim International GmbH | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| TR201007108A2 (tr) * | 2010-08-25 | 2012-03-21 | B�Lg�� Mahmut | Yeni tiotropyum bromür kristali ve üretim yöntemi.@ |
| EP2668177B1 (en) | 2011-01-28 | 2014-10-22 | Boehringer Ingelheim International GmbH | Substituted pyridinyl-pyrimidines and their use as medicaments |
| TR201101897A2 (tr) | 2011-02-28 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Tiotropyum bromür içeren kristal madde |
| TR201102068A2 (tr) | 2011-03-03 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Tiotropyum bromür içeren kristal maddeler |
| TR201111589A2 (tr) * | 2011-03-03 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Tiotropyum bromür susuz kristal formu. |
| WO2012171863A1 (en) | 2011-06-16 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| JP5786258B2 (ja) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規かつ選択的なｃｃｒ２拮抗薬 |
| PH12014500209A1 (en) | 2011-07-26 | 2014-03-03 | Boehringer Ingelheim Int | Substituted quinolines and their use as medicaments |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| HUE053745T2 (hu) | 2011-11-25 | 2021-07-28 | Adverio Pharma Gmbh | Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában |
| CZ304368B6 (cs) | 2011-11-28 | 2014-04-02 | Zentiva, K.S. | Směsný solvát tiotropium bromidu a způsob jeho přípravy |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| PT106142B (pt) * | 2012-02-10 | 2014-07-18 | Hovione Farmaci Ncia S A | Processo para a preparação de brometo de tiotrópio |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| EP2897955B1 (en) * | 2012-09-11 | 2019-11-06 | Bilgic, Mahmut | New tiotropium bromide crystalline form |
| ES2620758T3 (es) | 2012-11-05 | 2017-06-29 | Zentiva K.S. | Estabilización de solvatos de tiotropio |
| CN104341412A (zh) * | 2013-07-29 | 2015-02-11 | 天津金耀集团有限公司 | 一种无水噻托溴铵结晶的制备方法 |
| ES2738416T3 (es) | 2014-03-19 | 2020-01-22 | Boehringer Ingelheim Int | Inhibidores heteroarílicos de SYK |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| PT3209647T (pt) | 2014-10-21 | 2020-09-10 | Ariad Pharma Inc | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina |
| WO2017138896A1 (en) * | 2016-02-11 | 2017-08-17 | Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti | Crystalline form of tiotropium bromide anhydrate |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0418716A1 (de) * | 1989-09-16 | 1991-03-27 | Boehringer Ingelheim Kg | Neue Thienylcarbonsäureester von Aminoalkoholen, ihre Quaternierungsprodukte sowie die Herstellung und Verwendung dieser Verbindungen |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| AU2002214996B2 (en) * | 2000-10-12 | 2007-03-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| DE10064816A1 (de) * | 2000-12-22 | 2002-06-27 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Anticholinergikums |
-
2002
- 2002-06-08 CA CA2450961A patent/CA2450961C/en not_active Expired - Fee Related
- 2002-06-08 JP JP2003506910A patent/JP2005504015A/ja active Pending
- 2002-06-08 EA EA200301293A patent/EA005813B1/ru not_active IP Right Cessation
- 2002-06-08 MX MXPA03011718A patent/MXPA03011718A/es active IP Right Grant
- 2002-06-08 AU AU2002345016A patent/AU2002345016B2/en not_active Expired
- 2002-06-08 WO PCT/EP2002/006291 patent/WO2003000265A1/de not_active Ceased
- 2002-06-08 CN CN02812303A patent/CN100586948C/zh not_active Expired - Lifetime
- 2002-06-08 PL PL364489A patent/PL208137B1/pl unknown
- 2002-06-08 ES ES02743165T patent/ES2271280T3/es not_active Expired - Lifetime
- 2002-06-08 AT AT02743165T patent/ATE337006T1/de active
- 2002-06-08 PT PT02743165T patent/PT1401445E/pt unknown
- 2002-06-08 NZ NZ530690A patent/NZ530690A/en not_active IP Right Cessation
- 2002-06-08 RS YUP-997/03A patent/RS50441B/sr unknown
- 2002-06-08 SI SI200230431T patent/SI1401445T1/sl unknown
- 2002-06-08 KR KR1020037016769A patent/KR100971616B1/ko not_active Expired - Lifetime
- 2002-06-08 HR HR20031066A patent/HRP20031066B1/xx not_active IP Right Cessation
- 2002-06-08 HU HU0400333A patent/HUP0400333A3/hu unknown
- 2002-06-08 CZ CZ20040120A patent/CZ302786B6/cs not_active IP Right Cessation
- 2002-06-08 EE EEP200400029A patent/EE05316B1/xx unknown
- 2002-06-08 SK SK52-2004A patent/SK287262B6/sk unknown
- 2002-06-08 EP EP02743165A patent/EP1401445B1/de not_active Expired - Lifetime
- 2002-06-08 BR BR0210537-3A patent/BR0210537A/pt not_active Application Discontinuation
- 2002-06-08 DE DE50207943T patent/DE50207943D1/de not_active Expired - Lifetime
- 2002-06-08 IL IL15923802A patent/IL159238A0/xx unknown
- 2002-06-08 DK DK02743165T patent/DK1401445T3/da active
- 2002-06-08 KR KR1020097004823A patent/KR101011353B1/ko not_active Expired - Lifetime
- 2002-06-08 ME MEP-2008-620A patent/ME00412B/me unknown
- 2002-06-19 TW TW095100968A patent/TW200617007A/zh unknown
- 2002-06-19 EG EG2002060698A patent/EG24851A/xx active
- 2002-06-19 TW TW091113373A patent/TWI261589B/zh not_active IP Right Cessation
- 2002-06-20 MY MYPI20022316A patent/MY122779A/en unknown
- 2002-06-20 UY UY27342A patent/UY27342A1/es not_active Application Discontinuation
- 2002-06-21 PE PE2002000538A patent/PE20030130A1/es active IP Right Grant
- 2002-06-21 AR ARP020102337A patent/AR037491A1/es not_active Application Discontinuation
- 2002-06-21 PE PE2007000660A patent/PE20081305A1/es not_active Application Discontinuation
- 2002-08-19 SA SA2230255A patent/SA02230255B1/ar unknown
-
2003
- 2003-12-08 IL IL159238A patent/IL159238A/en active IP Right Grant
- 2003-12-12 BG BG108440A patent/BG66303B1/bg unknown
- 2003-12-19 NO NO20035696A patent/NO334301B1/no not_active IP Right Cessation
-
2004
- 2004-01-20 CO CO04003764A patent/CO5550423A2/es not_active Application Discontinuation
-
2006
- 2006-09-20 CY CY20061101339T patent/CY1105223T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0418716A1 (de) * | 1989-09-16 | 1991-03-27 | Boehringer Ingelheim Kg | Neue Thienylcarbonsäureester von Aminoalkoholen, ihre Quaternierungsprodukte sowie die Herstellung und Verwendung dieser Verbindungen |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101011353B1 (ko) | 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| KR100823860B1 (ko) | 결정성 1수화물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| US6777423B2 (en) | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions | |
| US6608055B2 (en) | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition | |
| CA2479652C (en) | Crystalline micronisate of tiotropium bromide | |
| IL187055A (en) | Crystalline forms of tiotropium bromide anhydride, a method for their preparation and pharmaceutical composition comprising them | |
| HK1068540B (en) | Crystalline anticholinergic, method for its production, and use thereof in the production of a drug | |
| HK1086557B (en) | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20031222 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20070607 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080424 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20081205 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20080424 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20090306 |
|
| PJ0201 | Trial against decision of rejection |
Patent event date: 20090306 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20081205 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20100628 Appeal identifier: 2009101002047 Request date: 20090306 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20090306 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20090306 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20080825 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20070607 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| E801 | Decision on dismissal of amendment | ||
| PB0601 | Maintenance of original decision after re-examination before a trial |
Comment text: Report of Result of Re-examination before a Trial Patent event code: PB06011S01D Patent event date: 20090422 |
|
| PE0801 | Dismissal of amendment |
Patent event code: PE08012E01D Comment text: Decision on Dismissal of Amendment Patent event date: 20090422 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20090306 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20080825 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20070607 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090306 Effective date: 20100628 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20100628 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20090306 Decision date: 20100628 Appeal identifier: 2009101002047 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20100715 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20100716 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20130705 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130705 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20140707 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140707 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20150703 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150703 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20160708 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160708 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20170707 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170707 Start annual number: 8 End annual number: 8 |
|
| PC1801 | Expiration of term |
Termination date: 20221208 Termination category: Expiration of duration |